In the US, currently only 1-2% of individuals who qualify for bariatric surgery or
anti-obesity medications (AOMs) receive them. Of individuals that receive bariatric
surgery, 20-25% experience significant weight regain or insufficient weight loss.
(
1
) The authors are to be commended for reporting their efforts to optimize patient
outcomes by combining bariatric surgery with AOMs in patients identified as high risk
for not meeting post-surgical weight targets including high initial BMI and insufficient
weight loss at 3 and 6 months post-op. The use of the expected weight loss curves
from the MBSAQIP risk/benefit calculator should be incorporated in post-operative
visits to help with early identification and early pharmacotherapeutic intervention.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgery for Obesity and Related DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Ref:
- Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps – a scoping review.Obes Surg. 2021; 31: 1755-1766
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.Lancet. 2011 Apr 16; 377: 1341-1352
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med. 2021 Mar 18; 384: 989-1002
- SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med. 2022 Jul 21; 387: 205-216
Article info
Publication history
Accepted:
March 12,
2023
Received:
February 15,
2023
Publication stage
In Press Journal Pre-ProofFootnotes
Disclosures:
Gelesis - consultant;
Lilly - consultant
Novo Nordisk - consultant, advisor, speaker
Note to editor: In the authors manuscript, anti-obesity medication does not need to be capitalized throughout the paper. Just as we would not capitalize anti-hypertensive medication. If the acronym is used, then of course capitalize as I have done here.
Identification
Copyright
© 2023 Published by Elsevier Inc. on behalf of American Society for Metabolic and Bariatric Surgery.
